Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Pharmacogenet Genomics. 2017 May;27(5):190–196. doi: 10.1097/FPC.0000000000000277

Figure 3.

Figure 3

Prevalence of the supratherapeutic voriconazole trough plasma concentration at steady state in CYP2C19 rapid and ultrarapid metabolizers combined (RMs and UMs), normal metabolizers (NMs) and intermediate and poor metabolizers combined (IMs and PMs).